Relationship Between Endothelial Function and Fibrinolysis in Early Hypertension

Hypertension

Volumn 31, Issue 1, 1998, Pages 321-327

  Tomiyama, Hirofumi ^a   Kimura, Yutaka ^a   Mitsuhashi, Hiroyuki ^a   Kinouchi, Takashi ^a   Yoshida, Hideo ^a   Kushiro, Toshio ^a   Doba, Nobutaka ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; AMLODIPINE; BENZAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTERY DIAMETER; ARTICLE; BORDERLINE HYPERTENSION; BRACHIAL ARTERY; CELL FUNCTION; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; FIBRINOLYSIS; HUMAN; HYPEREMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REGRESSION ANALYSIS; BLOOD; BLOOD PRESSURE; CAROTID ARTERY; DRUG EFFECT; ECHOCARDIOGRAPHY; ECHOGRAPHY; GLUCOSE TOLERANCE TEST; HEMOSTASIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; VASCULAR ENDOTHELIUM;

ADULT; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; BLOOD PRESSURE; BRACHIAL ARTERY; CALCIUM CHANNEL BLOCKERS; CAROTID ARTERIES; CHOLESTEROL; ECHOCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYSIS; GLUCOSE TOLERANCE TEST; HEMOSTASIS; HUMANS; HYPEREMIA; HYPERTENSION; INSULIN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; REFERENCE VALUES; REGRESSION ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES;

EID: 0031951452     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.31.1.321     Document Type: Article

References (32)

1. Ridker PM, Hennekens CH, Stamper MJ, Manson JAE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
2. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
3. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
4. Selwyn AP, Kinlay S, Creager M, Libby P, Ganz P. Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease. Am J Cardiol. 1997;79(5A):17-23.
5. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990;227:273-278.
6. Jeng JR, Sheu WHH, Jeng CY, Huang SH, Shieh SM. Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens. 1996;9:484-490.
7. Lijnen HR, Collen D. Endothelium in hemostasis and thrombosis. Prog Cardiovasc Dis. 1997;39:343-350.
8. Rubanyi GM. The role of endothelium in cardiovascular hemostasis and diseases. J Cardiovasc Pharm. 1993;22(suppl 4):S1-S14.
9. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis. 1997;39:287-324.
10. Winther K, Gleerup G, Hedner T. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and- adrenergic receptor blockers. J Cardiovasc Pharm. 1991;18(suppl 9):S41-S44.
11. Vaughan DE, Rouleau JL, Rdker PM, Arnold JMO, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation. 1997;96:442-447.
12. Lithell HOL. Effects of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203-209.
13. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Furukawa L, Asagami T, Hino T, Saito F, Otsuka Y, Kurumatani H, Kobayashi F, Kanmatsuse K, Kajiwara N. Kinins contirbute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension. 1994;23:450-455.
14. Pepine CJ. Improved endothelial function with angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997;79(5A):29-32.
15. Iwatsubo H, Nagano M, Sakai T, Kumamoto K, Morita R, Higaki J, Ogihara T, Hata T. Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension. 1997;29:286-290.
16. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
17. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC, Selwyn AP. Close relation of endothelial function in human coronary and peripheral circulation. J Am Coll Cardiol. 1995;26:1235-1241.
18. Sahn DJ, Demaria A Kisslo J, Weyman A. Recommendations recording quantification in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
19. Devereux RB, Reicheck N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation. 1977;55:613-618.
20. Tomiyama H, Doba N, Kushiro T, Yamashita M, Kanmatsuse K, Kajiwara N, Yoshida H, Hinohara S. Prospective studies on left ventricular geometric patterns and exercise tolerance in unmedicated men with borderline and mild by hypertension. J Hypertens. 1996;14:1223-1228.
21. Kaplan NM, ed. Primary hypertension: pathogenesis. In: Clinical Hypertension. Baltimore: Williams & Wilkins; 1990:47-108.
22. Diamond SL, Eskin SG, Molntyre LV. Fluid flow stimulates tissue plasminogen activator secretion by culture human endothelial cell. Science. 1989;243:1483-1485.
23. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. Circulation. 1995;91:284-290.
24. Robbie LA, Booth NA, Brown PAJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 1996;16:539-545.
25. Elliason M, Jansson JH, Nilsson P, Asplund K. Increased levels of tissue plasminogen activator antigen in essential hypertension, a population-based study in Sweden. J Hypertens. 1997;15:349-356.
26. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol. 1994;24:67-73.
27. Creager MA, Roddy MA. Effects of captopril and enalapril on endothelial function in hypertensive patients. Hypertension. 1994;24:499-505.
28. Tagawa T, Imaizumi T, Endo T, Shiramoto M, Harasawa Y, Takeshita A. Role of nitric oxide in reactive hyperemia in human forearm vessels. Circulation. 1994;90:2285-2290.
29. Loscalzo J, Vita JA. Ischemia, hyperemia, exercise, and nitric oxide complex physiology and complex molecular adaptations. Circulation. 1994;90:2556-2559.
30. Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol. 1993;21:1145-1151.
31. Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol. 1997;79(5A):12-16.
32. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. Circulation. 1994;89:321-330.